Our company has extensive experience in the characterization and optimization of monoclonal and polyclonal antibodies for research, diagnostic, and therapeutic applications. We offer a range of services to support the characterization and optimization of antibodies, including:
Antibody characterization: We use a range of techniques to characterize the quality and performance of antibodies, including SDS-PAGE and ELISA. We can also perform functional assays to assess the activity and specificity of antibodies, and can provide detailed reports on the performance of our products.
We have experience in the development of novel antibody formats, including antibody drug conjugates (ADCs), bi-specific antibodies, and monoclonal antibodies.
Custom services: We offer a range of custom services to support the development and optimization of antibodies, including assay development, and protein expression and purification. Our team of experts can work with you to design and execute customized projects that meet your specific needs and goals.
If you are looking to characterize or optimize antibodies for research, diagnostic, or therapeutic applications, we can provide the expertise and resources you need to succeed.
What are antibodies?
Monoclonal antibodies: These are produced from a single clone of cells, and are characterized by their high specificity and affinity for a particular target. Monoclonal antibodies are commonly used as research tools, diagnostics, and therapeutics.
Polyclonal antibodies: These are produced from multiple clones of cells, and are characterized by their broad specificity and lower affinity for a particular target. Polyclonal antibodies are commonly used as research tools and diagnostic reagents.
Recombinant antibodies: These are produced using genetic engineering techniques, and are characterized by their ability to be easily modified and expressed in large quantities. Recombinant antibodies are commonly used as research tools and therapeutics.
Humanized antibodies: These are produced by engineering non-human antibodies to have human-like properties, and are characterized by their reduced immunogenicity and increased pharmacokinetic properties. Humanized antibodies are commonly used as therapeutics.
Chimeric antibodies: These are produced by combining the variable regions of a non-human antibody with the constant regions of a human antibody, and are characterized by their ability to retain the specificity of the non-human antibody while minimizing immunogenicity. Chimeric antibodies are commonly used as therapeutics.
Bispecific antibodies: These are produced by engineering antibodies to bind to two different targets simultaneously, and are characterized by their ability to bridge two immune cells or two different epitopes on the same cell. Bispecific antibodies are being developed as therapeutics for cancer and other diseases.
Antibody drug conjugates (ADCs): These are produced by conjugating a cytotoxic drug to an antibody, and are characterized by their ability to selectively deliver the drug to target cells. ADCs are being developed as therapeutics for cancer and other diseases.
Contact Us Today
HTD has worked and collaborated with many companies, governments, and academia.
About us HTD is a private company located in Livermore, California. HTD has worked and collaborated with other companies, governments, and academia. Our researchers have helped other companies develop their products.
